T-cell receptor (TCR)-dependent treatment involves modified immune cells aimed at attacking particular tumor indicators. This treatment approach necessitates a systematic procedure including patient evaluation (e.g., for HLA-A*02:01 and precise tumor markers), collecting immune cells, creating the altered TCR produ...
Find MoreHematopoietic progenitor kinase (HPK1) belongs to the family of Ste20 serine/threonine kinases known as mitogen-activated protein kinase kinase kinase kinase (MAP4K). It is primarily expressed in hematopoietic cells and functions as a negative regulator of T-cell receptor (TCR) and B-cell signaling, serving as an i...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.